TapewireFind a company

person · Reporting owner

YOUNGBLOOD DR KNEELAND

Disclosed activity across 11 companies

Tapewire entity
39095
SEC CIK
0001137820

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
KPET Ultra Paceline CorpKPET · Entity 5979DirectorMarch 30, 2026March 30, 2026
Light & Wonder, Inc.ASX:LNW · Entity 9758DirectorJune 10, 2026June 13, 2026
Nerdy Inc.PACE · Entity 5208DirectorOctober 06, 2020October 06, 2020
Pharos Capital BDC, Inc.NONE · Entity 168323Director · Chief Executive OfficerMarch 13, 2018March 13, 2018
TPG Pace Beneficial Finance Corp.TPGY · Entity 131171DirectorOctober 06, 2020October 06, 2020
TPG Pace Beneficial II Corp.YTPG · Entity 131170DirectorApril 13, 2021April 13, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

KPET Ultra Paceline Corp

Report date March 30, 2026 · Filed March 30, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B Ordinary Shares, par value $0.0001 per shareSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2026-03-30 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The Class B Ordinary Shares are automatically convertible into the Issuer's Class A Ordinary Shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B Ordinary Shares are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the Issuer's Board of Directors.

Filing footnotes · ownership attribution and instrument terms

F1: The Class B Ordinary Shares are automatically convertible into the Issuer's Class A Ordinary Shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B Ordinary Shares are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the Issuer's Board of Directors.

Light & Wonder, Inc.

Report date June 10, 2026 · Filed June 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect30,555 Reported balance After 2026-06-10 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-10 · Exercise / conversion · Acquired 2,391 · Balance 30,555

F1: Shares are held via CHESS Depositary Interests ("CDIs"), which are units of beneficial ownership in shares of common stock of the Company that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty. Limited, a subsidiary of ASX Limited, the company that operates the ASX. Each CDI represents one fully paid share of common stock.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-10 · Exercise / conversion · Disposed 2,391 · Balance 0

F2: Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect2,498 Reported balance After 2026-06-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-06-10 · Grant · Acquired 2,498 · Balance 2,498

F3: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are held via CHESS Depositary Interests ("CDIs"), which are units of beneficial ownership in shares of common stock of the Company that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty. Limited, a subsidiary of ASX Limited, the company that operates the ASX. Each CDI represents one fully paid share of common stock.

F2: Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis.

F3: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis.

Nerdy Inc.

Report date October 06, 2020 · Filed October 06, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2020-10-06 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-248594). The Class F Ordinary Shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-248594). The Class F Ordinary Shares have no expiration date.

Pharos Capital BDC, Inc.

Report date March 13, 2018 · Filed March 13, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance Holding disclosure · report date 2018-03-13 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 0

TPG Pace Beneficial Finance Corp.

Report date October 06, 2020 · Filed October 06, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2020-10-06 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-248595). The Class F Ordinary Shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-248595). The Class F Ordinary Shares have no expiration date.

TPG Pace Beneficial II Corp.

Report date April 13, 2021 · Filed April 13, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2021-04-13 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333- 254008). The Class F Ordinary Shares have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333- 254008). The Class F Ordinary Shares have no expiration date.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Accel Entertainment, Inc.

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class F Ordinary SharesSEC Table II · derivative / convertible securityDirect0 Reported balance After 2019-11-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-11-20 · Sale · Disposed 40,000 · Balance 0

F1: Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.

Core Scientific, Inc./tx

Report date January 23, 2024 · Filed February 16, 2024 · Amendment

Section 16 reporting ended · disclosed 2024-02-16. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivativeDirect0 Reported balance After 2024-01-23 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2024-01-23 · Disposition to issuer · Disposed 400,038 · Balance 0

F1: On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.

F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),

F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

Common Stock, par value $0.00001 per shareSEC Table I · non-derivativeDirect40,004 Reported balance After 2024-01-23 transaction · row 2 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 2 · 2024-01-23 · Grant · Acquired 40,004 · Balance 40,004

F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),

F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

Tranche 1 WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2027-01-23Direct50,654 Reported balance After 2024-01-23 transaction · row 3 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 3 · 2024-01-23 · Grant · Acquired 50,654 · Balance 50,654

F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),

F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

F4: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price").

F5: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement.

Tranche 2 WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2029-01-23Direct42,212 Reported balance After 2024-01-23 transaction · row 4 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 4 · 2024-01-23 · Grant · Acquired 42,212 · Balance 42,212

F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),

F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

F4: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price").

F5: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.

F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),

F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

F4: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price").

F5: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement.

Keenova Therapeutics plc

Report date June 16, 2022 · Filed June 21, 2022

Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Pace Holdings Corp.

Report date March 10, 2017 · Filed March 14, 2017

Section 16 reporting ended · disclosed 2017-03-14. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class F Ordinary SharesSEC Table II · derivative / convertible securityIndirectSee Explanation of Responses0 Reported balance After 2017-03-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2017-03-10 · Disposition to issuer · Disposed 40,000 · Balance 0

F1: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

F2: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Youngblood is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

F2: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Youngblood is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer.

TPG Pace Solutions Corp.

Report date December 03, 2021 · Filed December 07, 2021

Section 16 reporting ended · disclosed 2021-12-07. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible securityDirect0 Reported balance After 2021-12-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-12-03 · Disposition to issuer · Disposed 40,000 · Balance 0

F1: Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share ("Class F Shares"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share ("Class A Shares"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment.

F2: In connection with the merger of the Issuer with and into Vacasa, Inc. ("Vacasa") pursuant to the Business Combination Agreement, as amended, dated as of July 28, 2021, by and among the Issuer, Vacasa and the other parties thereto, the Class F Shares were automatically cancelled, extinguished and converted, on a one-for-one basis, into shares of Class F Common Stock of Vacasa.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share ("Class F Shares"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share ("Class A Shares"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment.

F2: In connection with the merger of the Issuer with and into Vacasa, Inc. ("Vacasa") pursuant to the Business Combination Agreement, as amended, dated as of July 28, 2021, by and among the Issuer, Vacasa and the other parties thereto, the Class F Shares were automatically cancelled, extinguished and converted, on a one-for-one basis, into shares of Class F Common Stock of Vacasa.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 28, 2017 Filed Nov 30, 2017 09:08 UTC Keenova Therapeutics plc MNK · Entity 28960 PurchaseOrdinary Shares 4,560 $21.94 $100,046.40
Disclosure

SEC source: 0000950138-17-000770 · edgar.xml · nonDerivative · entry 1

YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,789

Read SEC document
October 01, 2017 Filed Oct 3, 2017 17:11 UTC Keenova Therapeutics plc MNK · Entity 28960 Tax withholdingOrdinary Shares 476 $37.37 $17,788.12
Disclosure

SEC source: 0000950138-17-000707 · edgar.xml · nonDerivative · entry 1

YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,229

Read SEC document
March 10, 2017 Filed Mar 14, 2017 18:44 UTC Pace Holdings Corp. PACE · Entity 177842 Disposition to issuerClass F Ordinary Shares · Derivative 40,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000903423-17-000191 · youngblood4.xml · derivative · entry 1

YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Explanation of Responses

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 40,000 shares

Expires not disclosed

F1 · derivative.exercise_price: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

F1 · price: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

F1 · derivative.exercise_date: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

F1 · derivative.expiration_date: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

F1 · ownership.nature: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

F2 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Youngblood is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer.

Read SEC document
March 01, 2017 Filed Mar 3, 2017 18:48 UTC Keenova Therapeutics plc MNK · Entity 28960 Tax withholdingOrdinary Shares 2,286 $51.55 $117,843.30
Disclosure

SEC source: 0000950138-17-000264 · edgar.xml · nonDerivative · entry 2

YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,705

Read SEC document
March 01, 2017 Filed Mar 3, 2017 18:48 UTC Keenova Therapeutics plc MNK · Entity 28960 GrantOrdinary Shares 5,723 $0.00 $0.00
Disclosure

SEC source: 0000950138-17-000264 · edgar.xml · nonDerivative · entry 1

YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,991

F1 · shares: Consists of restricted stock units that vest in their entirety as of March 1, 2018. The restricted stock units settle in ordinary shares upon vesting.

Read SEC document
October 01, 2016 Filed Oct 4, 2016 10:10 UTC Keenova Therapeutics plc MNK · Entity 28960 GrantOrdinary Shares 1,057 $0.00 $0.00
Disclosure

SEC source: 0000950138-16-001380 · edgar.xml · nonDerivative · entry 1

YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,268

F1 · shares: Consists of restricted stock units that vest in their entirety as of October 1, 2017. The restricted stock units settle in ordinary shares upon vesting.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.